Provider of life sciences sample management, genomics services and biological/cold-chain storage solutions for research and biobanking.
Provider of life sciences sample management, genomics services and biological/cold-chain storage solutions for research and biobanking.
Charges for sequencing and gene-synthesis work in labs and for storing, shipping and tracking biological samples, often under multi-year agreements. It was Brooks Automation until it sold its semiconductor automation business to Thomas H. Lee Partners and renamed itself, leaving a pure life-sciences company.
Moat: narrow (switching costs, scale, installed base). Long-term sample-storage contracts and integrated logistics create high switching costs for research customers.
Headquarters: Burlington, Massachusetts · Founded: 1994
Size Azenta (AZTA) is a United States Health Care company (Medical/Nursing Services) with a market value of $2.03B, the 1763rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $48.69 on 18 Nov 2026.
Performance Over six months the shares gained 162.2%, against +19.1% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 4.7% over the last twelve months (peer median +9.2%); the operating margin is -2.3% (peer median 7.5%).
Valuation It trades at 83.2× forward earnings against a peer median of 33.8× (most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 38% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +34 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 13.2 points below its cost of capital (12.2% WACC).
Backlog Backlog (remaining performance obligations) was $64.0M at 30 Jun 2026, down 16% on a year earlier — 0.1 years of trailing revenue. Backlog detail →
Short interest Short interest is 12.3% of the free float (30 Oct 2026).
Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | $622M | $622M | $594M | $573M | $665M |
| Revenue growth | — | +5% | +4% | -14% | — |
| Gross profit | $275M | $275M | $270M | $255M | $233M |
| EBITDA | $42.4M | $35.9M | $49.9M | $60.8M | $3.39M |
| Net income | -$167M | -$167M | -$55.8M | -$165M | -$14.3M |
| Free cash flow | $27.4M | $27.4M | $38.3M | $12.4M | -$21.9M |
| Capital expenditure | $30.1M | $30.1M | $33.9M | $37.4M | $39.4M |
| Total debt | $51.9M | $51.9M | $59.9M | $66.3M | $72.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Azenta AZTA | $2.03B | +162% | +5% | -2% | 83.2× | 38.0% |
| Thermo Fisher Scientific TMO | $257B | +53% | +8% | 19% | 25.7× | 21.3% |
| Charles River Laboratories CRL | $16.0B | +114% | -1% | 15% | 26.2× | 25.6% |
| Illumina ILMN | $31.8B | +48% | +6% | 21% | 35.2× | 27.2% |
| Eurofins Scientific ERF.PA | $16.4B | +37% | +3% | 12% | 22.1× | 12.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AZTA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +36.3% | -2.8% | highest of 21 |
| 6-month return | +162.2% | +19.1% | highest of 21 |
| Distance from 52-week high | -2.7% | -22.4% | 2nd highest of 21 |
| Revenue growth (TTM) | +4.7% | +9.2% | 10th lowest of 21 |
| Operating margin | -2.3% | 7.5% | 6th lowest of 21 |
| Forward P/E | 83.2× | 33.8× | most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 38.0% | 5.4% | 3rd most demanding of 16 |
| Growth delivered (Del g) | +3.9% | +8.5% | 6th lowest of 16 |
| Hurdle (Req g minus delivered) | +34.1 pp | +5.7 pp | most demanding of 16 |
| ROIC minus cost of capital | -13.2 pp | -3.4 pp | 5th lowest of 20 |
| EV / EBITDA | 41.4× | 11.9× | 2nd most expensive of 13 |
| Net debt / EBITDA | -6.6× | 2.2× | 2nd least indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Azenta AZTA | United States | $2.03B | +162% | +5% | -2% | 83.2× | 38.0% | +3.9% |
| NeoGenomics NEO | United States | $1.98B | +72% | +11% | -6% | 53.5× | n/a | n/a |
| AddLife ALIF-B.ST | Sweden | $2.13B | +15% | +2% | 8% | 39.0× | 21.1% | +14.6% |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.86B | +20% | +26% | 15% | 77.1× | 43.0% | +26.9% |
| Guangzhou Kingmed Diagnostics 603882.SS | China | $1.86B | +5% | -3% | 7% | 29.9× | 5.4% | -6.1% |
| Addus HomeCare ADUS | United States | $2.25B | +29% | +12% | 11% | 16.2× | 4.0% | +13.2% |
| Emeis EMEIS.PA | France | $1.78B | -33% | +4% | 3% | n/a | 21.2% | +8.5% |
| Aveanna Healthcare AVAH | United States | $2.37B | +41% | +17% | 12% | 12.2× | 7.7% | +10.2% |
| Pediatrix Medical MD | United States | $2.41B | +37% | +2% | 12% | 12.4× | -4.4% | +2.0% |
| Dian Diagnostics 300244.SZ | China | $1.70B | +1% | -5% | 9% | 21.8× | 0.3% | -1.1% |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.69B | +18% | +24% | 32% | 63.0× | 40.4% | +16.7% |
| Personalis PSNL | United States | $1.62B | +88% | +17% | -157% | n/a | n/a | n/a |
| Sonida Senior Living SNDA | United States | $1.59B | -11% | +70% | -8% | n/a | n/a | n/a |
| Ambea AMBEA.ST | Sweden | $1.59B | +28% | +11% | 9% | 15.2× | 1.1% | +7.7% |
| Meinian Onehealth Healthcare 002044.SZ | China | $2.60B | -27% | -4% | 9% | 49.6× | 4.2% | +5.7% |
| GeneDx WGS | United States | $1.56B | +16% | +15% | -14% | 54.2× | n/a | n/a |
| agilon health AGL | United States | $1.52B | +12% | +2% | -2% | 34.1× | n/a | n/a |
| Teladoc Health TDOC | United States | $1.47B | +24% | -2% | -5% | n/a | -6.4% | +18.3% |
| H.U.Group 4544.T | Japan | $1.44B | +24% | +1% | 3% | 39.9× | 9.7% | +2.1% |
| U.S. Physical Therapy USPH | United States | $1.42B | +53% | +10% | 10% | 29.4× | 18.8% | +13.0% |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.36B | -47% | +8% | 3% | 33.5× | 3.5% | -5.1% |
Azenta reported $64.0M of remaining performance obligations at 30 Jun 2026, down 16% from a year earlier and down 1% from the previous quarter. That is 0.1 years of trailing revenue already under contract. Book-to-bill last quarter: 1.00.